Who We Are
We are a team of highly motivated, talented and passionate individuals who share the vision of changing the treatment landscape for patients living with a less common disease.
Aspreva's vision
Aspreva's vision is to change the treatment landscape for people living with less common diseases by increasing the pool of evidence-based medicines available for these patients.
What we do
Aspreva is focused on addressing the needs of individuals with less common diseases through the identification, development and commercialization of existing medicines for new indications.
Aspreva uses a proprietary screening program to identify late stage and approved medicines that show potential for high therapeutic impact in less common diseases. We then partner with pharmaceutical and biopharmaceutical companies to acquire the rights to develop the drug in these new indications, including clinical research and regulatory approvals. Once approved, we apply a strategic and specialized approach to commercializing products for these complex therapeutic categories.
Our expertise lies in the clinical, regulatory and commercial development of products for complex diseases and specialized patient populations which differs significantly from traditional pharmaceutical activities.
Aspreva is a leader in this new era of pharmaceutical partnering.
For more information about our partnerships, please visit the Partners page. For information on our current research, please visit Clinical Trials.
Why we do it
Aspreva is driven by a desire to enrich the lives of millions of patients worldwide who are affected by less common diseases. We believe we can make a valuable contribution to the management of these diseases by delivering effective, evidence-based treatments.
Our partnering strategy enables pharmaceutical and biopharmaceutical companies to develop their drugs, clinically and commercially outside of their products' strategic focus. It is the strength of our partnerships that deliver real benefit to our patients.
Copyright 2006 - Aspreva Pharmaceuticals Corporation -